Synergistic Induction of Oxidative Injury and Apoptosis in Human Multiple Myeloma Cells by the Proteasome Inhibitor Bortezomib and Histone Deacetylase Inhibitors

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Clinical Cancer Research

• Publication date

  2004-06-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1158/1078-0432.CCR-03-0561PMID 15173093
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Histone Deacetylase Inhibitors for Cancer Therapy

  2006cited by this paper
• Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.

  2003cited by this paper
• The proteasome: structure, function, and role in the cell.

  2003cited by this paper
• NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.

  2003cited by this paper
• The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.

  2003cited by this paper
• Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.

  2003cited by this paper
• Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.

  2003cited by this paper
• Molecular sequelae of histone deacetylase inhibition in human malignant B cells.

  2003influential reference
• A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells

  2003cited by this paper
• Clinical update: proteasome inhibitors in hematologic malignancies.

  2003cited by this paper
• The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.

  2003cited by this paper
• Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells.

  2003cited by this paper
• Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-κB-dependent process

  2003cited by this paper
• Inhibition of c-Jun N-terminal kinase pathway improves cell viability in response to oxidant injury.

  2003cited by this paper
• A phase 2 study of bortezomib in relapsed, refractory myeloma.

  2003influential reference
• Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

  2003cited by this paper
• An Intact NF-kappaB Pathway is Required for Histone Deacetylase Inhibitor Induced G1 Arrest and Maturation in U937 Human Myeloid Leukemia Cells

  2003cited by this paper
• Reactive Oxygen Species Generation and Mitochondrial Dysfunction in the Apoptotic Response to Bortezomib, a Novel Proteasome Inhibitor, in Human H460 Non-small Cell Lung Cancer Cells*

  2003cited by this paper
• JNK-dependent Release of Mitochondrial Protein, Smac, during Apoptosis in Multiple Myeloma (MM) Cells*

  2003cited by this paper
• Interleukin‐1β converting enzyme subfamily inhibitors prevent induction of CD86 molecules by butyrate through a CREB‐dependent mechanism in HL60 cells

  2003cited by this paper
• A review of the cytokine network in multiple myeloma

  2003cited by this paper
• The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

  2003influential reference
• Histone Deacetylase Inhibitors in Cancer Therapy

  2003cited by this paper
• Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)

  2002cited by this paper
• Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism.

  2002cited by this paper
• E2F1 and c-Myc potentiate apoptosis through inhibition of NF-kappaB activity that facilitates MnSOD-mediated ROS elimination.

  2002cited by this paper
• Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

  2002cited by this paper
• Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

  2002cited by this paper
• Role of caspase 3-dependent Bcl-2 cleavage in potentiation of apoptosis by Bcl-2.

  2002cited by this paper
• Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors

  2002cited by this paper
• The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells.

  2002cited by this paper
• Clinical activity of arsenic trioxide for the treatment of multiple myeloma

  2002cited by this paper
• Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications.

  2002influential reference
• Diagnosis and management of multiple myeloma.

  2001cited by this paper
• Histone acetylases—versatile players

  2001cited by this paper
• Ionizing radiation-induced, mitochondria-dependent generation of reactive oxygen/nitrogen.

  2001cited by this paper
• The AKT kinase is activated in multiple myeloma tumor cells.

  2001cited by this paper
• Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity.

  2001cited by this paper
• Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells.

  2001cited by this paper
• Apaf-1/Cytochrome c-independent and Smac-dependent Induction of Apoptosis in Multiple Myeloma (MM) Cells*

  2001cited by this paper
• The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

  2001cited by this paper
• The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma.

  2001cited by this paper
• Butyrate Suppression of Colonocyte NF-κB Activation and Cellular Proteasome Activity*

  2001cited by this paper
• The role of nuclear factor-?b in the biology and treatment of multiple myeloma

  2001cited by this paper
• Histone deacetylases and cancer: causes and therapies

  2001cited by this paper
• Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells.

  2001cited by this paper
• Insulin‐like growth factor induces the survival and proliferation of myeloma cells through an interleukin‐6‐independent transduction pathway

  2000cited by this paper
• Cytokines prevent dexamethasone-induced apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in a new multiple myeloma cell line.

  2000cited by this paper
• The apoptotic effects and synergistic interaction of sodium butyrate and MG132 in human retinoblastoma Y79 cells.

  1999cited by this paper
• Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53

  1999cited by this paper
• Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis

  1995cited by this paper
• A mechanism of resistance to glucocorticoids in multiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA.

  1992cited by this paper
• Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein.

  1986cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper
• British Committee for Standards in Haematology

  1969cited by this paper

• The effects of gut microbiota-derived short-chain fatty acids (SCFAs) on human colon cancer cells: An in vitro study

  2025cites this paper
• Enhanced anticancer effect of carfilzomib by codelivery of calcium peroxide nanoparticles targeting endoplasmic reticulum stress

  2025cites this paper
• Impact of proteostasis workload on sensitivity to proteasome inhibitors in multiple myeloma

  2025cites this paper
• Deciphering the dynamics of histone acetylation and chromatin remodeling in multiple myeloma: a tale beyond the tails.

  2025cites this paper
• HDAC inhibitors activate lipid peroxidation and ferroptosis in gastric cancer.

  2024cites this paper
• Trajectory, interactions, and predictors of higher symptom burden during induction therapy for multiple myeloma

  2024cites this paper
• ST2825, independent of MyD88, induces reactive oxygen species-dependent apoptosis in multiple myeloma cells

  2024cites this paper
• Soluble epoxide hydrolase inhibition alleviates chemotherapy induced neuropathic pain

  2023cites this paper
• Sequential Ubiquitination and Phosphorylation Epigenetics Reshaping by MG132‐Loaded Fe‐MOF Disarms Treatment Resistance to Repulse Metastatic Colorectal Cancer

  2023cites this paper
• Bortezomib and Vorinostat Therapy as Maintenance Therapy Post-Autologous Transplant for Non-Hodgkin’s Lymphoma Using R-BEAM or BEAM Transplant Conditioning Regimen

  2023cites this paper
• Hypoxia‐induced oxidative stress promotes therapy resistance via upregulation of heme oxygenase‐1 in multiple myeloma

  2023cites this paper
• Calcium signaling in chemotherapy-induced neuropathy.

  2023cites this paper
• Histone deacetylase‐based dual targeted inhibition in multiple myeloma

  2023influential citation
• Potential of Synthetic and Natural Compounds as Novel Histone Deacetylase Inhibitors for the Treatment of Hematological Malignancies

  2023cites this paper
• Asymptomatic unilateral phrenic nerve palsy after bortezomib treatment in a newly diagnosed multiple myeloma patient

  2022cites this paper
• Multifunctional liposomal nanostructure-mediated siRNA/bortezomib co-delivery for SHARP1 knockdown in MLL-AF6 acute myeloid leukemia.

  2022cites this paper
• Dual-Targeted Therapy Circumvents Non-Genetic Drug Resistance to Targeted Therapy

  2022cites this paper
• Modulation of Cellular Redox Parameters for Improving Therapeutic Responses in Multiple Myeloma

  2022cites this paper
• Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives

  2021cites this paper
• Chidamide, a subtype-selective histone deacetylase inhibitor, enhances Bortezomib effects in multiple myeloma therapy

  2021cites this paper
• Peripheral Neuropathy and Pain Caused by Cancer Chemotherapy

  2021cites this paper
• Histone deacetylase inhibitors (HDACi), the ongoing epigenetic agents to enhance chemotherapy sensitization

  2021cites this paper
• Synergistic anticancer effect of a combination of chidamide and etoposide against NK/T cell lymphoma

  2021cites this paper
• Synergistic effect of Chloroquine and Panobinostat in ovarian cancer through induction of DNA damage and inhibition of DNA repair

  2021cites this paper
• The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma

  2021cites this paper
• Genome Instability in Multiple Myeloma: Facts and Factors

  2021cites this paper
• Network-Based Systems Analysis Explains Sequence-Dependent Synergism of Bortezomib and Vorinostat in Multiple Myeloma

  2021cites this paper
• Investigating the Interplay between Myeloma Cells and Bone Marrow Stromal Cells in the Development of Drug Resistance: Dissecting the Role of Epigenetic Modifications

  2021cites this paper
• Overcome the tumor immunotherapy resistance by combination of the HDAC6 inhibitors with antitumor immunomodulatory agents.

  2021cites this paper
• Multifunctional nanoparticle-mediated SHARP1 knockdown in MLL-AF6 acute myeloid leukemia

  2021cites this paper
• Promising Anti-Mitochondrial Agents for Overcoming Acquired Drug Resistance in Multiple Myeloma

  2021cites this paper
• Dysregulation of the Ubiquitin Proteasome System in Human Malignancies: A Window for Therapeutic Intervention

  2021cites this paper
• The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges

  2020cites this paper
• Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistance

  2020cites this paper
• Recent advances in small molecular modulators targeting histone deacetylase 6

  2020cites this paper
• Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas

  2020cites this paper
• Clinical efficiency of epigenetic drugs therapy in bone malignancies.

  2020cites this paper
• Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome

  2020cites this paper
• The safety of current and emerging therapies for multiple myeloma

  2020cites this paper
• Proteotoxic Stress and Cell Death in Cancer Cells

  2020cites this paper
• Chemosensitization of Tumor Cells by Phenolic Antioxidants: The Role of the Nrf2 Transcription Factor

  2020cites this paper
• Histone Deacetylation

  2020cites this paper
• Symptom burden and its functional impact in patients with “symptomatic” relapsed or refractory multiple myeloma

  2020cites this paper
• Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies

  2020cites this paper
• Actionable Strategies to Target Multiple Myeloma Plasma Cell Resistance/Resilience to Stress: Insights From “Omics” Research

  2020cites this paper
• Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard and high risk myeloma.

  2020cites this paper
• Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease

  2020cites this paper
• Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma

  2020cites this paper
• Restoring MLL reactivates latent tumor suppression-mediated vulnerability to proteasome inhibitors

  2020cites this paper
• Bortezomib and Vorinostat Therapy as Maintenance Therapy after Autologous Transplant for Multiple Myeloma

  2019cites this paper
• Impact of Body Mass Index on the Incidence of Bortezomib-induced Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma.

  2019cites this paper
• Pluronic block copolymers enhance the anti-myeloma activity of proteasome inhibitors.

  2019cites this paper
• Regulation of Calcineurin Signaling Through Blocking of the Chaperone Function of Hsp90 by HDAC Inhibitors

  2019cites this paper
• The γ-secretase inhibitor GSI-I interacts synergistically with the proteasome inhibitor bortezomib to induce ALK+ anaplastic large cell lymphoma cell apoptosis.

  2019cites this paper
• Proteasome Inhibitors as Sensitizing Agents for Cancer Chemotherapy

  2019cites this paper
• Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13

  2019cites this paper
• HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action

  2019cites this paper
• Prevention of chemotherapy-induced peripheral neuropathy: A review of recent findings.

  2019cites this paper
• From tea to treatment; epigallocatechin gallate and its potential involvement in minimizing the metabolic changes in cancer.

  2019cites this paper
• Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy

  2019cites this paper
• Proteasome inhibitors trigger mutations via activation of caspases and CAD, but mutagenesis provoked by the HDAC inhibitors vorinostat and romidepsin is caspase/CAD-independent

  2019cites this paper
• Neurological Complications of Chemotherapy

  2018cites this paper
• Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi

  2018cites this paper
• Cancer Neurology in Clinical Practice

  2018cites this paper
• A mitochondrial FUNDC1/HSC70 interaction organizes the proteostatic stress response at the risk of cell morbidity

  2018cites this paper
• The Multiple Myeloma Drug Pipeline—2018: A Review of Small Molecules and Their Therapeutic Targets

  2018cites this paper
• Proteomic approach for understanding milder neurotoxicity of Carfilzomib against Bortezomib

  2018cites this paper
• Panobinostat and Multiple Myeloma in 2018

  2018cites this paper
• Counteracting survival functions of EBNA3C in Epstein-Barr virus (EBV)-driven lymphoproliferative diseases by combination of SAHA and bortezomib

  2018cites this paper
• Treatment of Patients in First or Second Relapse

  2018cites this paper
• Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma

  2018cites this paper
• A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B‐cell Lymphoma

  2018cites this paper
• Synergistic antitumor effect of histone deacetylase inhibitor and Doxorubicin in peripheral T-cell lymphoma.

  2017cites this paper
• Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma

  2017influential citation
• Targeting histone deacetylases in T-cell lymphoma

  2017cites this paper
• Proteasome inhibitors in glioblastoma

  2017cites this paper
• Chapter 2 Resistance to Proteasome Inhibitors in Multiple Myeloma

  2017cites this paper
• The integrated stress response and proteotoxicity in cancer therapy.

  2017cites this paper
• Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics

  2017cites this paper
• Bortezomib Enhances the Antitumor Effects of Interferon-β Gene Transfer on Melanoma Cells.

  2017cites this paper
• Investigating the mechanisms by which histone deacetylase inhibitors induce apoptosis in cancer cells

  2017cites this paper
• Enhancement of death receptor-mediated apoptosis in multiple myeloma cells

  2017cites this paper
• Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma

  2017cites this paper
• Small molecule CP-31398 induces reactive oxygen species-dependent apoptosis in human multiple myeloma

  2017cites this paper
• Belinostat exerts antitumor cytotoxicity through the ubiquitin‐proteasome pathway in lung squamous cell carcinoma

  2017cites this paper
• Panobinostat for the management of multiple myeloma.

  2017cites this paper
• Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms

  2017cites this paper
• Oxidative Stress Gene Expression Profile Correlates with Cancer Patient Poor Prognosis: Identification of Crucial Pathways Might Select Novel Therapeutic Approaches

  2017cites this paper
• Therapeutic Strategies against Epstein-Barr Virus-Associated Cancers Using Proteasome Inhibitors

  2017cites this paper
• Histone Deacetylase Inhibitors as Anticancer Drugs

  2017cites this paper
• Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma

  2017cites this paper
• Plant Derived Inhibitor Sulforaphane in Combinatorial Therapy Against Therapeutically Challenging Pancreatic Cancer.

  2017cites this paper
• Novel tropolones induce the unfolded protein response pathway and apoptosis in multiple myeloma cells

  2017cites this paper
• Cell Signaling Model Connects Vorinostat Pharmacokinetics and Tumor Growth Response in Multiple Myeloma Xenografts

  2017cites this paper
• Sequential Exposure of Bortezomib and Vorinostat is Synergistic in Multiple Myeloma Cells

  2017cites this paper
• 12 Novel Therapeutic Targets in Soft Tissue Sarcomas

  2017cites this paper
• Clinical use and applications of histone deacetylase inhibitors in multiple myeloma

  2016cites this paper
• Drugging the undruggables: exploring the ubiquitin system for drug development

  2016cites this paper
• Cyclin D1 unbalances the redox status controlling cell adhesion, migration, and drug resistance in myeloma cells

  2016cites this paper
• Targeting unique oxidative metabolism of clonogenic multiple myeloma cells for therapy

  2016cites this paper